.Pharmacolibrary.Drugs.ATC.A.A02BC03

Information

Lansoprazole is a proton pump inhibitor (PPI) used to reduce gastric acid secretion. It is indicated for the treatment of gastroesophageal reflux disease (GERD), peptic ulcer disease, and Zollinger–Ellison syndrome. Lansoprazole is currently approved and widely used in clinical practice.

Pharmacokinetics

Pharmacokinetic parameters reported in healthy adult subjects, following single oral administration in fasting state.

References

1. Echizen, H (2016). The First-in-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations. Clinical pharmacokinetics 55(4) 409–418. DOI:10.1007/s40262-015-0326-7 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26369775

2. Yu, L, et al., & Zhang, Y (2023). Pharmacokinetics and Pharmacodynamics of Lansoprazole/Sodium Bicarbonate Immediate-release Capsules in Healthy Chinese Subjects: An Open, Randomized, Controlled, Crossover, Single-, and Multiple-dose Trial. Clinical pharmacology in drug development 12(9) 902–910. DOI:10.1002/cpdd.1251 PUBMED:https://pubmed.ncbi.nlm.nih.gov/37165834

3. Youssef, AF, et al., & Fort, FL (2003). Safety and pharmacokinetics of oral lansoprazole in preadolescent rats exposed from weaning through sexual maturity. Reproductive toxicology (Elmsford, N.Y.) 17(1) 109–116. DOI:10.1016/s0890-6238(02)00099-0 PUBMED:https://pubmed.ncbi.nlm.nih.gov/12507665

Revisions

• 06/2025 initial generated model